Patient subgroups included: patients with HBV-monoinfection treated with lamivudine (n = 36), adefovir (n = 32), entecavir (n = 32), or tenofovir (n = 37). HBsAg-positive untreated patients (n = 60) served as control. For comparison HIV-monoinfected patients treated with tenofovir (n = 120) or zidovudine (n = 52) based antiretroviral therapy and antiretroviral naive patients (n = 109) were assessed. CKD-EPI equation was used to calculate eGFR. In a more sensitive approach, we modeled the individual change in eGFR over time with linear mixed effects models (LME).
Yearly predicted median changes in individual eGFR according to the LME model were: HBV untreated ?.05 ml/min, HBV lamivudine ?.92 ml/min, HBV adefovir ?.02 ml/min, HBV entecavir ?.00 ml/min, and HBV tenofovir ?.92 ml/min (p <0.01 for HBV untreated vs. HBV treated). In HIV-monoinfected patients: HIV untreated ?.62 ml/min, HIV treated with tenofovir ?.64 ml/min, HIV treated with zidovudine ?.0 ml/min (p = 0.017 for tenofovir vs. no treatment, p <0.001 for tenofovir vs. zidovudine).
Therapy of HBV infection irrespective of medication seems to result in a milder decrease of renal function. In contrast tenofovir as part of HIV combination therapy seems to impair renal function in this Caucasian population.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址:北京市海淀区学院路29号 邮编:100083 电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700 |